{"id":"pf-06940434","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04152018"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2024","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.) — Squamous Cell Carcinoma of the Head and Neck. Trial terminated early."}],"brandName":"PF-06940434","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2","explanation":"","oneSentence":"PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 2","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"pf-06940434","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Squamous Cell Carcinoma of the Head and Neck","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04152018","phase":"discontinued","title":"Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":85,"indication":"Squamous Cell Carcinoma of the Head and Neck","completionDate":"2024-12","primaryEndpoint":"Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in "}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL4518706"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","aiSummary":"Pf-06940434, developed by Pfizer Inc., was a discontinued drug. Its mechanism of action and intended indications are not available in the provided information.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}